1
|
Magnani C, Pastore G, Luzzatto L, Terracini B. Parental Occupation and Other Environmental Factors in the Etiology of Leukemias and Non-Hodgkin'S Lymphomas in Childhood: A Case-Control Study. Tumori 2018; 76:413-9. [PMID: 2256184 DOI: 10.1177/030089169007600501] [Citation(s) in RCA: 108] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
We report the results of a hospital-based, case-control study on acute lymphocytic leukemia (ALL), acute non-lympocytic leukemia (AnLL) and non-Hodgkin lymphoma (NHL) in childhood. The study was conducted from 1981 to 1984 in Turin (Italy). One hundred and forty-two children with ALL, 22 with AnLL and 19 with NHL were included, as well as 307 controls. Information on parental smoking habits, parental occupation, ionizing radiation and childhood diseases were collected using a standard questionnaire during a personal interview of the relative attending the child in the hospital. The odds ratios for antenatal diagnostic radiation were 1.1 (NS) for ALL and 2.4 (NS) for AnLL. No association was found with diseases in childhood. Paternal and maternal smoking habits were similar for ALL cases and controls. Both maternal and paternal smoking were associated with NHL: for paternal smoking, odds ratios were around 5, but without a correlation with number of cigarettes. Positive associations observed with maternal employment were: ALL with teacher and cleaner; AnLL and textile worker; NHL and baker. Corresponding association with paternal jobs were: ALL with clerks, farmers and employment in office equipment production; AnLL and workers in building, tire or textile industries; NHL and lorry drivers, workers in the building or in the wood and furniture industry.
Collapse
Affiliation(s)
- C Magnani
- Cancer Epidemiology Unit, University of Torino, Italy
| | | | | | | |
Collapse
|
2
|
Abstract
A hospital-based case-control study on soft tissue sarcomas (STS) was conducted in 1983-84 in Torino and in Padova (Italy). Cases (36 children with rhabdomyosarcoma (RMS) and 16 non RMS-STS) were compared to 326 controls. Histories of parental smoking habits and occupations, parental and children's exposure to ionizing radiation, children's diseases and some other variables were collected through interviews to the relatives attending the child in the hospital. A non statistically significant association was observed with both maternal age above 30 at child's birth (STS: OR = 1.5, C.I. = 0.8-2.9; RMS: OR = 1.9, C.I. = 0.9-4.0) and « in utero » exposure to diagnostic radiation (STS: OR = 1.9, C.I. = 0.5-6.5, based on 4 cases). No association was found with children's previous diseases. Paternal and maternal smoking habits were similar for RMS and STS cases and controls. Some positive associations with either maternal or paternal occupational histories were identified. They are difficult to interpret in view of the large number of comparisons and small absolute figures. They included maternal employment as medical doctor and nurse, farmer, textile worker and machine tool operator. An association was also observed with paternal occupation as butcher, building worker or employment in the production of domestic appliances. One case and no controls reported a maternal aunt affected by breast cancer.
Collapse
Affiliation(s)
- C Magnani
- Cancer Epidemiology Unit, University of Torino, Italy
| | | | | | | | | | | |
Collapse
|
3
|
Pastore G, Mosso ML, Magnani C, Luzzatto L, Bianchi M, Terracini B. Physical Impairment and Social Life, Goals among Adult Long-term Survivors of Childhood Cancer: A Population-based Study from the Childhood Cancer Registry of Piedmont, Italy. Tumori 2018; 87:372-8. [PMID: 11989588 DOI: 10.1177/030089160108700603] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and Background The study describes the health status and the attainment of life goals in the adult survivors of childhood cancer recorded at the Childhood Cancer Registry of Piedmont. Methods and Study Design A postal questionnaire was sent to the general practitioner of the 690 cases born before 1976 and alive in 1991 after at least 5 years from diagnosis. The answer was received for 485 (72.9%) included in the analyses. Items in the questionnaire were: sequelae related to cancer and its treatment, health-related quality of life (according to Bloom's criteria), educational level attained, and employment status. Results Vital and marital status were obtained for all 690 cases at the offices of the town of residence. No medical condition was reported for 309 cases (63.7%). The overall proportion with a high school or university education was compared to corresponding figures for Piedmont in 1991, adjusted by age, and was as high as in the general population. Similar results are observed for occupation. Patients of both genders were married less than expected. Patients with leukemia (112 cases), non-Hodgkin's lymphoma (34) or Hodgkin's lymphoma (52) were reported to have the highest quality of life. In contrast, patients with tumors of the central nervous system (151) had the highest frequency of sequelae and the lowest score for health-related quality of life. They also presented the lowest educational achievement, the lowest proportion of employment and, among males, the lowest frequency of marriage. Conclusions Our study shows a good social adjustment of adult survivors from childhood cancer, with the exception of central nervous system tumors. From the methodologic point of view, the present study shows the feasibility of surveillance surveys on health-related quality of life with the contribution of general practitioners.
Collapse
Affiliation(s)
- G Pastore
- Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit of the Centre for Cancer Epidemiology and Prevention, CPO Piedmont, San Giovanni Hospital, Turin, Italy
| | | | | | | | | | | |
Collapse
|
4
|
Luzzatto L, Loupakis F. Comprehensive Cancer Care Networks: A realistic model for optimising outcomes and minimising inequalities. Eur J Public Health 2016. [DOI: 10.1093/eurpub/ckw172.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Relling MV, McDonagh EM, Chang T, Caudle KE, McLeod HL, Haidar CE, Klein T, Luzzatto L. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther 2014; 96:169-74. [PMID: 24787449 DOI: 10.1038/clpt.2014.97] [Citation(s) in RCA: 97] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2014] [Accepted: 04/27/2014] [Indexed: 02/02/2023]
Abstract
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with development of acute hemolytic anemia (AHA) induced by a number of drugs. We provide guidance as to which G6PD genotypes are associated with G6PD deficiency in males and females. Rasburicase is contraindicated in G6PD-deficient patients due to the risk of AHA and possibly methemoglobinemia. Unless preemptive genotyping has established a positive diagnosis of G6PD deficiency, quantitative enzyme assay remains the mainstay of screening prior to rasburicase use. The purpose of this article is to help interpret the results of clinical G6PD genotype tests so that they can guide the use of rasburicase. Detailed guidelines on other aspects of the use of rasburicase, including analyses of cost-effectiveness, are beyond the scope of this document. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are published and updated periodically on https://www.pharmgkb.org/page/cpic to reflect new developments in the field.
Collapse
Affiliation(s)
- M V Relling
- Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - E M McDonagh
- Department of Genetics, Stanford University, Stanford, California, USA
| | - T Chang
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - K E Caudle
- Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - H L McLeod
- Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida, USA
| | - C E Haidar
- Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - T Klein
- Department of Genetics, Stanford University, Stanford, California, USA
| | - L Luzzatto
- Department of Hematology, Istituto Toscano Tumori, Firenze, Italy
| | | |
Collapse
|
6
|
Caldarella A, Amunni G, Angiolini C, Crocetti E, Di Costanzo F, Di Leo A, Giusti F, Pegna AL, Mantellini P, Luzzatto L, Paci E. Feasibility of evaluating quality cancer care using registry data and electronic health records: a population-based study. Int J Qual Health Care 2012; 24:411-8. [DOI: 10.1093/intqhc/mzs020] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
|
7
|
Bonaccorsi L, Nesi G, Nuti F, Paglierani M, Krausz C, Masieri L, Serni S, Proietti-Pannunzi L, Fang Y, Jhanwar SC, Orlando C, Carini M, Forti G, Baldi E, Luzzatto L. Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results. J Endocrinol Invest 2009; 32:590-6. [PMID: 19494719 DOI: 10.1007/bf03346514] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND The recently identified TMPRSS2: ERG fusion gene is a candidate oncogene for prostate cancer (PCa). SUBJECTS AND METHODS We have tested for the presence of this gene in tumor samples from 84 patients who had radical prostatectomy in 1998-2000. Sixty patients (group A) had surgery only; 24 patients (group B) received androgen ablation therapy for 3 months before surgery. The occurrence of the rearrangement was evaluated by RT-PCR and by fluorescent in situ hybridization analysis. RESULTS A TMPRSS2:ERG fusion gene was present and expressed, as demonstrated by RT-PCR, in 84% of patients in group A and in 54% of patients in group B (p=0.01). The presence of TMPRSS2:ERG transcripts and the levels of ERG RNA, measured by quantitative Real Time-PCR, did not correlate significantly with clinical and pathologic characteristics of the tumors. In patients of group A, but not in those of group B, ERG expression showed a negative correlation with the Gleason score (p=0.0001). Histochemical analysis showed that ERG expression is limited to tumor cells, and in group A patients (but not in group B patients) it is limited to those glands that express TMPRSS2:ERG. CONCLUSION The lower proportion of patients expressing TMPRSS2: ERG in group B suggests that androgen ablation inhibits the expression of TMPRSS2:ERG. Moreover, in group B, but not in group A, patients with expression of the fusion gene had earlier prostate specific antigen recurrence (p=0.007). Although preliminary, the data indicate that tumors in which pre-surgery androgen ablation fails to suppress expression of the fusion gene have a higher risk of recurrence.
Collapse
Affiliation(s)
- L Bonaccorsi
- Unit of Andrology, Department of Clinical Physiopathology, University of Florence, Florence, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Foroni L, Foldi J, Matutes E, Catovsky D, O'Connor NJ, Baer R, Forster A, Rabbitts TH, Luzzatto L. α, β and γ T-cell receptor genes: rearrangements correlate with haematological phenotype in T cell leukaemias. Br J Haematol 2008. [DOI: 10.1111/j.1365-2141.1987.00307.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Abstract
A family is described in which the father and son had erythrocytosis associated with a normal Hb oxygen affinity. Growth of erythroid colonies in vitro (BFU-E) exhibited normal erythropoietin dependence. In the son there was an enlarged erythroid precursor compartment, while the father (who had been treated by busulphan) showed marked reduction of circulating BFU-Es. Serum erythropoietin (Epo), estimated by radio-immunoassay, was 96 miu/ml in the son and 360 miu/ml in the father (normal 25, SD 6, n = 46). We conclude that erythrocytosis in this family is due to a genetically determined hyper-production of Epo. The finding in the father of a high Hb level associated with increased Epo and decreased BFU-Es might support the hypothesis that red cell mass is regulated by Epo at the level of bone marrow CFU-Es rather than BFU-Es.
Collapse
|
10
|
Luzzatto L, Sodeinde O, Martini G. Genetic variation in the host and adaptive phenomena in Plasmodium falciparum infection. Ciba Found Symp 2008; 94:159-73. [PMID: 6341000 DOI: 10.1002/9780470715444.ch10] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The in vitro culture of Plasmodium falciparum, after synchronization, lends itself well to an analysis of the asexual schizogonic cycle. We have found in this system that DNA synthesis and RNA synthesis are associated mainly with the trophozoite stage, with the latter peaking slightly ahead of the former. Distinctive patterns of protein synthesis are seen at serial times along the cycle, with a number of 'stage-specific' bands identifiable on SDS gels. The fate of the infection can be influenced by the genotype of the host cell. Thus, glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes are invaded normally, but maturation of intracellular parasites is delayed and impaired. However, the parasites that do develop will then have a normal behaviour in their next rounds in G6PD-deficient cells, suggesting that an adaptive change has taken place. These results fit well with the relative protection against P. falciparum in vivo of girls heterozygous for G6PD deficiency but not of hemizygous G6PD-deficient boys.
Collapse
|
11
|
Schubert J, Young MD NS, Luzzatto L, Brodsky RA, Socié G, Rother RP, Rollins SA, Hillmen P. Lack of correlation of eculizumab therapy in paroxysmal nocturnal hemoglobinuria (PNH) patients with myeloproliferative disorders, myelodysplastic syndromes, acute leukemias or aplastic anemia with long-term treatment. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.7092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Schubert J, Young NS, Luzzatto L, Brodsky RA, Socié G, Rother RP, Rollins SA, Hillmen P. Evaluation of risk for development of myeloproliferative disorders, myelodysplastic syndromes, or acute leukemias with long-term eculizumab therapy in paroxysmal nocturnal hemoglobinuria (PNH) patients. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7087 Background: PNH is a rare bone marrow failure disorder defined by stem cell clones with somatic mutations in the PIG-A gene. These mutations result in peripheral blood cells deficient in GPI-anchored proteins including complement inhibitors CD55 and CD59. Chronic lysis of PNH RBCs leads to severe anemia, life-threatening thrombosis, debilitating fatigue, and impaired quality of life. Previous studies have indicated an increased frequency of myeloproliferative disorders, MDS, and acute leukemias in PNH. In a previous retrospective analysis of 1,760 PNH patients, 6.8% developed either myeloid or lymphoid disorders and 1% developed acute leukemias. Eculizumab (Soliris) is a humanized antibody that prevents terminal complement activation. Long-term eculizumab treatment has been evaluated in 195 PNH patients (>250 patient years of exposure) and shown to significantly restore the endogenous PNH RBC clone resulting in improved anemia, as well as significant improvements in thrombosis, fatigue, and quality of life. Methods: Leukocyte clone sizes were assessed at baseline and 26 weeks for patients receiving eculizumab in the Phase III clinical trials (TRIUMPH and SHEPHERD) using flow cytometry. The frequency of MDS and leukemia was calculated as a percentage of the eculizumab-treated patients across all eculizumab trials. Results: PNH leukocyte clone size did not increase with eculizumab treatment (median 96.1% at baseline vs 95.5% at week 26; P=0.80, signed rank test) suggesting that inhibition of terminal complement does not destroy or result in the proliferation of PNH leukocyte clones. Additionally, the frequency of new MDS (1/195 patients, 0.5%) and CMML (1/195 patients, 0.5%) during the treatment period was not increased over that expected. The single case of CMML occurred in a patient previously diagnosed with and was attributed to high grade myelodysplasia. Conclusions: To date, eculizumab treatment of PNH patients does not increase the risk for the development of myeloproliferative disorders, MDS or acute leukemias. Patients on eculizumab will continue to be followed in a Global PNH Safety Registry. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Schubert
- Saarland University Medical School, Homburg/Saar, Germany; National Heart, Lung, and Blood Institute, Bethesda, MD; Istituto Toscano Tumori, Firenze, Italy; Johns Hopkins University School of Medicine, Baltimore, MD; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; Leeds General Infirmary, Leeds, United Kingdom
| | - N. S. Young
- Saarland University Medical School, Homburg/Saar, Germany; National Heart, Lung, and Blood Institute, Bethesda, MD; Istituto Toscano Tumori, Firenze, Italy; Johns Hopkins University School of Medicine, Baltimore, MD; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; Leeds General Infirmary, Leeds, United Kingdom
| | - L. Luzzatto
- Saarland University Medical School, Homburg/Saar, Germany; National Heart, Lung, and Blood Institute, Bethesda, MD; Istituto Toscano Tumori, Firenze, Italy; Johns Hopkins University School of Medicine, Baltimore, MD; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; Leeds General Infirmary, Leeds, United Kingdom
| | - R. A. Brodsky
- Saarland University Medical School, Homburg/Saar, Germany; National Heart, Lung, and Blood Institute, Bethesda, MD; Istituto Toscano Tumori, Firenze, Italy; Johns Hopkins University School of Medicine, Baltimore, MD; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; Leeds General Infirmary, Leeds, United Kingdom
| | - G. Socié
- Saarland University Medical School, Homburg/Saar, Germany; National Heart, Lung, and Blood Institute, Bethesda, MD; Istituto Toscano Tumori, Firenze, Italy; Johns Hopkins University School of Medicine, Baltimore, MD; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; Leeds General Infirmary, Leeds, United Kingdom
| | - R. P. Rother
- Saarland University Medical School, Homburg/Saar, Germany; National Heart, Lung, and Blood Institute, Bethesda, MD; Istituto Toscano Tumori, Firenze, Italy; Johns Hopkins University School of Medicine, Baltimore, MD; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; Leeds General Infirmary, Leeds, United Kingdom
| | - S. A. Rollins
- Saarland University Medical School, Homburg/Saar, Germany; National Heart, Lung, and Blood Institute, Bethesda, MD; Istituto Toscano Tumori, Firenze, Italy; Johns Hopkins University School of Medicine, Baltimore, MD; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; Leeds General Infirmary, Leeds, United Kingdom
| | - P. Hillmen
- Saarland University Medical School, Homburg/Saar, Germany; National Heart, Lung, and Blood Institute, Bethesda, MD; Istituto Toscano Tumori, Firenze, Italy; Johns Hopkins University School of Medicine, Baltimore, MD; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; Leeds General Infirmary, Leeds, United Kingdom
| |
Collapse
|
13
|
Brodsky RA, Hillmen P, Schubert J, Luzzatto L, Socié G, Mojcik CF, Rother RP, Young NS. Safety and efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria evolving from patients with myelodysplastic syndrome and aplastic anemia. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7033 Background: Myelodysplastic syndrome (MDS) and aplastic anemia (AA) have been reported to be associated with the development of the acquired clonal hemolytic and bone marrow failure disorder, paroxysmal nocturnal hemoglobinuria (PNH). Two recent phase 3 clinical studies have demonstrated significant benefit of the complement inhibitor eculizumab (Soliris) in a heterogeneous population of patients with PNH (n=140). Methods: To investigate whether eculizumab was safe and effective in PNH patients with a history of MDS or AA (n=37), efficacy parameters were examined in the MDS/AA patient subpopulation. Results: Intravascular hemolysis, as assessed by plasma levels of the enzyme lactate dehydrogenase (LDH), was reduced from a mean of 1871 ± 159 U/L at baseline to 300 ± 21 U/L at week 26 in patients with a history of MDS or AA (p<0.001, signed rank test; normal range 103–223 U/L). Anemia was improved as packed RBC transfusion requirements were substantially reduced with eculizumab in these patients from a median of 8 units per patient in the 6 months before treatment to 0 units per patient during eculizumab treatment (p<0.001, signed rank test). Despite history of bone marrow failure, eculizumab treatment markedly improved fatigue with an 11.6 point increase over baseline using the FACIT-Fatigue instrument (p<0.001, signed rank test; a 3 or more point increase in this instrument has been shown to be clinical meaningful). Fatigue was similarly improved with the fatigue scale of the EORTC QLQ-C30 instrument (p<0.001, signed rank test). Eculizumab appeared to be well tolerated when administered to PNH patients with a history of MDS or AA. The significant clinical improvements in hematologic and quality of life outcomes with eculizumab treatment in PNH patients with a history of MDS or AA were similar to the clinical improvements demonstrated the overall PNH patient population. Conclusions: These analyses show that eculizumab treatment may provide important clinical benefit when administered to PNH patients with a history of bone marrow failure. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. A. Brodsky
- Johns Hopkins University School of Medicine, Baltimore, MD; Leeds General Infirmary, Leeds, United Kingdom; Saarland University Medical School, Homburg/Saar, Germany; Istituto Toscano Tumori, Firenze, Italy; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; National Heart, Lung, and Blood Institute, Bethesda, MD
| | - P. Hillmen
- Johns Hopkins University School of Medicine, Baltimore, MD; Leeds General Infirmary, Leeds, United Kingdom; Saarland University Medical School, Homburg/Saar, Germany; Istituto Toscano Tumori, Firenze, Italy; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; National Heart, Lung, and Blood Institute, Bethesda, MD
| | - J. Schubert
- Johns Hopkins University School of Medicine, Baltimore, MD; Leeds General Infirmary, Leeds, United Kingdom; Saarland University Medical School, Homburg/Saar, Germany; Istituto Toscano Tumori, Firenze, Italy; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; National Heart, Lung, and Blood Institute, Bethesda, MD
| | - L. Luzzatto
- Johns Hopkins University School of Medicine, Baltimore, MD; Leeds General Infirmary, Leeds, United Kingdom; Saarland University Medical School, Homburg/Saar, Germany; Istituto Toscano Tumori, Firenze, Italy; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; National Heart, Lung, and Blood Institute, Bethesda, MD
| | - G. Socié
- Johns Hopkins University School of Medicine, Baltimore, MD; Leeds General Infirmary, Leeds, United Kingdom; Saarland University Medical School, Homburg/Saar, Germany; Istituto Toscano Tumori, Firenze, Italy; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; National Heart, Lung, and Blood Institute, Bethesda, MD
| | - C. F. Mojcik
- Johns Hopkins University School of Medicine, Baltimore, MD; Leeds General Infirmary, Leeds, United Kingdom; Saarland University Medical School, Homburg/Saar, Germany; Istituto Toscano Tumori, Firenze, Italy; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; National Heart, Lung, and Blood Institute, Bethesda, MD
| | - R. P. Rother
- Johns Hopkins University School of Medicine, Baltimore, MD; Leeds General Infirmary, Leeds, United Kingdom; Saarland University Medical School, Homburg/Saar, Germany; Istituto Toscano Tumori, Firenze, Italy; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; National Heart, Lung, and Blood Institute, Bethesda, MD
| | - N. S. Young
- Johns Hopkins University School of Medicine, Baltimore, MD; Leeds General Infirmary, Leeds, United Kingdom; Saarland University Medical School, Homburg/Saar, Germany; Istituto Toscano Tumori, Firenze, Italy; Hospital Saint Louis and INSERM, Paris, France; Alexion Pharmaceuticals Inc, Cheshire, CT; National Heart, Lung, and Blood Institute, Bethesda, MD
| |
Collapse
|
14
|
Mojcik CF, Young NS, Luzzatto L, Socié G, Hillmen P, Brodsky RA. Safety and efficacy of eculizumab with concomitant erythropoietin therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3032 Background: Erythropoietins (EPO) are commonly used to improve anemia in patients with bone marrow failure syndromes and in patients with chemotherapy-induced anemia. Two recent phase 3 clinical studies have demonstrated significant benefit of the terminal complement inhibitor, eculizumab (Soliris), in a heterogeneous population of patients with the acquired clonal hemolytic and bone marrow failure disorder, PNH (n=140). While previous studies have shown that EPO is associated with only moderate improvements in fatigue in anemic cancer patients (effect size of 0.5), eculizumab has demonstrated large improvements in fatigue in PNH patients (effect size of 1.1). Methods: To investigate whether eculizumab provides further benefit to PNH patients receiving EPO, efficacy parameters were examined in the EPO subpopulation (n=8). Results: Intravascular hemolysis, as assessed by plasma levels of lactate dehydrogenase (LDH) area under the curve, was reduced 268,271 U/L x day to near normal levels in EPO-treated patients during 26 weeks of eculizumab therapy (p=0.008, signed rank test). Anemia was improved as packed RBC transfusion requirements were substantially reduced with eculizumab in EPO patients from a median of 7.5 units per patient in the 6 months before treatment to 1 unit per patient during eculizumab treatment (p=0.031, signed rank test). Despite pre-existing EPO and transfusion support, eculizumab treatment markedly improved fatigue with a 7.3 point increase over baseline using the FACIT-fatigue instrument (p=0.016, signed rank test; a 3 or more point increase in this instrument has been shown to be clinically meaningful). Eculizumab was well tolerated when administered to PNH patients treated with concomitant EPO with adverse events similar to the overall population. The significant clinical improvements in hematologic and quality of life outcomes with eculizumab treatment in PNH patients receiving concomitant EPO were similar to the clinical improvements demonstrated in the overall PNH patient population. Conclusions: These analyses show that eculizumab treatment provides important clinical benefit when administered to PNH patients receiving EPO support for bone marrow failure. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. F. Mojcik
- Alexion Pharmaceuticals Inc, Cheshire, CT; National Heart, Lung, and Blood Institute, Bethesda, MD; Istituto Toscano Tumori, Firenze, Italy; Hospital Saint Louis and INSERM, Paris, France; Leeds General Infirmary, Leeds, United Kingdom; Johns Hopkins University School of Medicine, Baltimore, MD
| | - N. S. Young
- Alexion Pharmaceuticals Inc, Cheshire, CT; National Heart, Lung, and Blood Institute, Bethesda, MD; Istituto Toscano Tumori, Firenze, Italy; Hospital Saint Louis and INSERM, Paris, France; Leeds General Infirmary, Leeds, United Kingdom; Johns Hopkins University School of Medicine, Baltimore, MD
| | - L. Luzzatto
- Alexion Pharmaceuticals Inc, Cheshire, CT; National Heart, Lung, and Blood Institute, Bethesda, MD; Istituto Toscano Tumori, Firenze, Italy; Hospital Saint Louis and INSERM, Paris, France; Leeds General Infirmary, Leeds, United Kingdom; Johns Hopkins University School of Medicine, Baltimore, MD
| | - G. Socié
- Alexion Pharmaceuticals Inc, Cheshire, CT; National Heart, Lung, and Blood Institute, Bethesda, MD; Istituto Toscano Tumori, Firenze, Italy; Hospital Saint Louis and INSERM, Paris, France; Leeds General Infirmary, Leeds, United Kingdom; Johns Hopkins University School of Medicine, Baltimore, MD
| | - P. Hillmen
- Alexion Pharmaceuticals Inc, Cheshire, CT; National Heart, Lung, and Blood Institute, Bethesda, MD; Istituto Toscano Tumori, Firenze, Italy; Hospital Saint Louis and INSERM, Paris, France; Leeds General Infirmary, Leeds, United Kingdom; Johns Hopkins University School of Medicine, Baltimore, MD
| | - R. A. Brodsky
- Alexion Pharmaceuticals Inc, Cheshire, CT; National Heart, Lung, and Blood Institute, Bethesda, MD; Istituto Toscano Tumori, Firenze, Italy; Hospital Saint Louis and INSERM, Paris, France; Leeds General Infirmary, Leeds, United Kingdom; Johns Hopkins University School of Medicine, Baltimore, MD
| |
Collapse
|
15
|
Luzzatto L, Notaro R, Gianfaldoni G. 18 Paroxysmal nocturnal hemoglobinuria. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70019-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
16
|
Amanti C, Catracchia V, Conte S, Luzzatto L, Lo Russo M, Marino G, Moscaroli A. [Breast surgery in HIV-positive women]. G Chir 2004; 25:180-2. [PMID: 15382477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
The increasing of HIV infection in young women as well as prolonged survival let us to register an important rising of breast cancers in such type of patients. The Authors report the case of a 48 year old HIV-positive woman, who underwent surgery because of the histological positivity for cancer of the right breast. It was decided to perform a quadrantectomy and reconstruction with implant, because of the absence of immunodepression. The Authors discuss about indications for reconstructive surgery in seropositive women with breast cancer.
Collapse
Affiliation(s)
- C Amanti
- Università degli Studi La Sapienza di Roma, II Facoltà di Medicina e Chirurgia, Ospedale Sant'Andrea, Dipartimento di Chirurgia
| | | | | | | | | | | | | |
Collapse
|
17
|
Midiri G, Eleuteri E, Coppola M, Giarnieri E, Marino G, Di Giovan Paolo M, De Francesco GP, Luzzatto L, Maceratini R, Angelini L. [Is the Lauren classification an independent parameter for the prognostic evaluation of surgically treated gastric cancer patients? Analysis of a case series]. G Chir 2003; 24:403-5. [PMID: 15018407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
The Authors highlight the efficacy of the Lauren's classification in 28 surgically treated gastric cancer patients. Lauren's classification allows a prognostic evaluation corresponding to the effective gastric cancer natural history. Present histo-morphological classification criteria appear not to coincide with the clinical evolution; as a matter of fact over- or understaging is possible in gastric cancer patients. 64,28% of the Lauren's classification intestinal type patients survive after a four year follow up vs. 42,85% of the diffuse type patients. The Authors discuss about new biomolecular knowledge in gastric cancer oncogenesis.
Collapse
Affiliation(s)
- G Midiri
- Università degli Studi "La Sapienza" di Roma, II Facoltà di Medicina e Chirurgia, Chirurgia B
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Midiri G, Papaspiropoulos V, Coppola M, Eleuteri E, Tucci G, Conte S, Marino G, Luzzatto L, Angelini L. [Telementoring in surgery]. G Chir 2003; 24:382-4. [PMID: 14723000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/28/2023]
Abstract
Tele-mentoring is an interactive experimental method that allows young surgeons' education by distant learning tutoring of an expert surgeon. The problem about assessment of efficacy and quality of computer-assisted instruction is under evaluation today. Tele-mentoring is supported by videoconferencing system and it is not an exclusive methodology but an additional methodology to traditional didactic for clinicians and surgeons. It allows personal virtual trainings by computers and telecommunication systems. Videoconference allows tutoring for telemedicine, teletriage and telesurgery also.
Collapse
Affiliation(s)
- G Midiri
- Il Facoltà di Medicina e Chirurgia, Università degli Studi La Sapienza, Roma
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Luzzatto L. The spectrum of molecular lesions in human tumors. Pathologica 2003; 95:221-3. [PMID: 14988975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023] Open
Affiliation(s)
- L Luzzatto
- Istituto Nazionale Ricerca sul Cancro, IST, Genova
| |
Collapse
|
20
|
Midiri G, Giarnieri E, Covotta A, Soda G, Tucci G, Consorti F, Pacella M, Gidaro S, Covotta L, Luzzatto L, Cirolla VA, Conte S, Marino G, Vecchione A, Beltrami V. [Changes in the expression of cellular alpha and beta tubulins in patients with sporadic type colorectal cancer]. G Chir 2003; 24:171-3. [PMID: 12945166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
The aim of this preliminar report is to evaluate alfa and beta tubulins, components of cellular microtubules, alterated expression in sporadic colorectal cancer patients. The Authors considered 16 patients who underwent surgery for sporadic colorectal carcinoma with radical intent. Alfa and beta tubulins were evaluated in tumoral mucosa by immunohistochemistry. In 56.2% of the examined patients a low expression of alfa and beta tubulins was showed while the alteration of alfa tubulin was showed in 81.2% of the patients. This finding supports the hypothesis of Porter that alterations in microtubule structure might be part of the cellular response to DNA damage.
Collapse
Affiliation(s)
- G Midiri
- II Facoltà di Medicina e Chirurgia Chirurgia Generale B, Ospedale Sant'Andrea, Università degli Studi La Sapienza, Roma
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Giarnieri E, Midiri G, Cirolla VA, Covotta A, Covotta L, Avitto FM, Luzzatto L, Marino G, Conte S, Vecchione A, Beltrami V. [From molecular biology to new treatment approaches to colorectal cancer: basic research, experimental trials and surgical implications]. G Chir 2003; 24:109-14. [PMID: 12886747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
The Authors review the natural history of colorectal cancer from the point of view of molecular biology and genetics from aberrant crypts foci and familiar adenomatous polyposis to hereditary non polyposis colon cancer and sporadic colorectal cancer. They carry out international literature about basis knowledges, experimental trials and personal studies. Up to day traditional colorectal cancer surgical treatments and adjuvant or neoadjuvant pharmacological therapy cannot be modified, nevertheless "new drugs generation" known as signal transduction inhibitor could, in the future, prove to be an effective cancer treatment. The Authors highlight recent experimental clinical trials probably able to prevent sporadic colorectal cancer spreading and precursor evolution.
Collapse
MESH Headings
- Adenomatous Polyposis Coli/genetics
- Angiogenesis Inhibitors/therapeutic use
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents/therapeutic use
- Apoptosis/genetics
- Cetuximab
- Clinical Trials as Topic
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Colorectal Neoplasms/drug therapy
- Colorectal Neoplasms/genetics
- Colorectal Neoplasms/surgery
- Colorectal Neoplasms, Hereditary Nonpolyposis/genetics
- ErbB Receptors/antagonists & inhibitors
- Follow-Up Studies
- Gefitinib
- Genes, APC
- Genes, DCC
- Genes, p53
- Genes, ras
- Humans
- Indoles/therapeutic use
- Mutation
- Prognosis
- Protein-Tyrosine Kinases/antagonists & inhibitors
- Pyrroles/therapeutic use
- Quinazolines/therapeutic use
- Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors
- Research
- Time Factors
Collapse
Affiliation(s)
- E Giarnieri
- II Facoltà di Medicina e Chirurgia, Oncologia, Ospedale Sant'Andrea, Università degli Studi La Sapienza, Roma
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Mussolin L, Basso K, Pillon M, D'Amore ES, Lombardi A, Luzzatto L, Zanesco L, Rosolen A. Prospective analysis of minimal bone marrow infiltration in pediatric Burkitt's lymphomas by long-distance polymerase chain reaction for t(8;14)(q24;q32). Leukemia 2003; 17:585-9. [PMID: 12646948 DOI: 10.1038/sj.leu.2402828] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The chromosomal translocation t(8;14)(q24;q32) represents a characteristic marker for Burkitt's lymphoma (BL). This translocation involves the MYC oncogene on chromosome 8 and the immunoglobulin heavy-chain (IgH) locus on chromosome 14. Since the translocation does not produce a fusion gene, we established a long-distance polymerase chain reaction (LD-PCR) assay that can detect the t(8;14) at the genomic level. The sensitivity of the LD-PCR was 10(-4). We used the LD-PCR assay to prospectively study 78 BL patients and found a specific PCR product in 52 of them. Among the 52 positive patients, we could test both the tumor and the bone marrow (BM) at diagnosis in 33 and determined the prevalence of minimal disseminated disease (MDD) at diagnosis. In 12/33 patients, BM was positive by LD-PCR and in 10 of them we conducted a study of minimal residual disease (MRD). Eight out of 10 children showed a clearance of MRD after one cycle of chemotherapy. The only two patients who did not achieve a negative MRD status died of disease progression. The comparative analysis of sensitivity of BM aspirate, BM biopsy and LD-PCR in t(8;14)-positive patients demonstrated a superiority of the molecular method in the assessment of MDD. The LD-PCR for t(8;14) is an important tool to study minimal BM infiltration at diagnosis and to determine its response kinetics in BL.
Collapse
Affiliation(s)
- L Mussolin
- Clinica di Oncoematologia Pediatrica, Azienda Ospedaliera-Università di Padova, Italy
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Araten DJ, Bessler M, McKenzie S, Castro-Malaspina H, Childs BH, Boulad F, Karadimitris A, Notaro R, Luzzatto L. Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones. Leukemia 2002; 16:2243-8. [PMID: 12399968 DOI: 10.1038/sj.leu.2402694] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
PNH is characterized by expansion of one or more stem cell clones with a PIG-A mutation, which causes a severe deficiency in the expression of glycosylphosphatidylinositol (GPI)-anchored proteins. There is evidence that the expansion of PIG-A mutant clones is concomitant with negative selection against PIG-A wild-type stem cells by an aplastic marrow environment. We studied 36 patients longitudinally by serial flow cytometry, and we determined the proportion of PNH red cells and granulocytes over a period of 1-6 years. We observed expansion of the PNH blood cell population(s) (at a rate of over 5% per year) in 12 out of 36 patients; in all other patients the PNH cell population either regressed or remained stable. The dynamics of the PNH cell population could not be predicted by clinical or hematologic parameters at presentation. These data indicate that in most cases the PNH cell expansion has already run its course by the time of diagnosis. In addition, since in most cases no further expansion takes place, we can infer that the tendency to overgrow normal cells is not an intrinsic property of the PNH clone.
Collapse
Affiliation(s)
- D J Araten
- Department of Medicine, Hematology Division, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Amanti C, Moscaroli A, Lo Russo M, Papaspyropoulos V, Luzzatto L, Catracchia V, Macchione B, Pucciatti I, Regolo L, Coppola M, Angelini L. [Periareolar subcutaneous quadrantectomy: a new approach in breast cancer surgery]. G Chir 2002; 23:445-9. [PMID: 12652922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
Plastic and oncological breast surgery are becoming more and more closer as one surgical treatment. The term "oncoplastic surgery" refers to the use of plastic surgery techniques in breast cancer surgery, in order to avoid and to correct the adverse aesthetic findings. The care of cosmetic sequelae of breast cancer surgery has reached an important therapeutic role for psychological consequences of disease and because of the higher patients expectations of a good aesthetic result. Considering the concept of oncoplastic surgery, since 1999 the Authors began to use a periareloar approach in the breast conserving therapy (BCT), associated to axillary dissection performed through the same periareolar incision. This technique, original from the oncological point of view, is not different from the traditional quadrantectomy in the extension of the glandular resection, while the skin may be preserved in according to the conventional protocols of BCT. Oncological and aesthetic results have proved to be safe and satisfactory.
Collapse
Affiliation(s)
- C Amanti
- Servizio di Senologia, Cattedra di Chirurgia Generale, Dipartimento di Scienze Chirurgiche F. Durante, Università degli Studi La Sapienza, Roma
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Karadimitris A, Li K, Notaro R, Araten DJ, Nafa K, Thertulien R, Ladanyi M, Stevens AE, Rosenfeld CS, Roberts IA, Luzzatto L. Association of clonal T-cell large granular lymphocyte disease and paroxysmal nocturnal haemoglobinuria (PNH): further evidence for a pathogenetic link between T cells, aplastic anaemia and PNH. Br J Haematol 2001; 115:1010-4. [PMID: 11843843 DOI: 10.1046/j.1365-2141.2001.03172.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
There is mounting evidence to suggest that T-cell-mediated suppression of haemopoiesis is a pathogenetic mechanism in three bone marrow failure syndromes: aplastic anaemia (AA), paroxysmal nocturnal haemoglobinuria (PNH) and myelodysplasia (MDS). T-cell microclones can be detected by sensitive polymerase chain reaction (PCR)-based methods in all three disorders. Recently, larger clonal populations of T-cell large granular lymphocytes (T-LGLs) have been observed in some patients with AA and MDS. Here, we report the development of a large clonal T-LGL population in a patient with bona fide PNH. In this patient, we defined part of the sequence of the T-cell receptor (TCR) beta-chain gene, and we have shown that the large T-LGL population emerged from a background of multiple smaller T-cell clones. Thus, T-LGL clones in AA, MDS and PNH probably expand as a result of antigenic stimulation. It is postulated that the antigen driving clonal T-cell proliferations in these disorders exists on haemopoietic stem cells.
Collapse
Affiliation(s)
- A Karadimitris
- Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Araten DJ, Swirsky D, Karadimitris A, Notaro R, Nafa K, Bessler M, Thaler HT, Castro-Malaspina H, Childs BH, Boulad F, Weiss M, Anagnostopoulos N, Kutlar A, Savage DG, Maziarz RT, Jhanwar S, Luzzatto L. Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria. Br J Haematol 2001; 115:360-8. [PMID: 11703336 DOI: 10.1046/j.1365-2141.2001.03113.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by the expansion of a haematopoietic stem cell clone with a PIG-A mutation (the PNH clone) in an environment in which normal stem cells are lost or failing: it has been hypothesized that this abnormal marrow environment provides a relative advantage to the PNH clone. In patients with PNH, generally, the karyotype of bone marrow cells has been reported to be normal, unlike in myelodysplastic syndrome (MDS), another clonal condition in which cytogenetic abnormalities are regarded as diagnostic. In a retrospective review of 46 patients with a PNH clone, we found a karyotypic abnormality in 11 (24%). Upon follow-up, the proportion of cells with abnormal karyotype decreased significantly in seven of these 11 patients. Abnormal morphological bone marrow features reminiscent of MDS were common in PNH, regardless of the karyotype. However, none of our patients developed excess blasts or leukaemia. We conclude that in patients with PNH cytogenetically abnormal clones are not necessarily malignant and may not be predictive of evolution to leukaemia.
Collapse
Affiliation(s)
- D J Araten
- Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Affiliation(s)
- L Luzzatto
- Department of Human Genetics, Memorial Sloan Kettering Center, New York, NY, USA.
| |
Collapse
|
28
|
Abstract
Paroxysmal nocturnal haemoglobinuria (PNH) is a unique disorder characterised by the triad of intravascular haemolysis, thrombosis and bone marrow failure. In the early seventies it was shown that PNH is a clonal disease; and in the nineties the molecular basis of the PNH abnormality was elucidated. However, what makes a PNH clone expand is still not known. Here, we suggest that this is due to somatic cell selection, resulting from the presence in the patient of autoreactive T cells that target glycosylphosphatidylinositol (GPI) in the context of an MHC-like molecule on the surface of haemopoietic stem cells. PNH cells would escape damage precisely because they have lost most or all of their ability to produce GPI.
Collapse
|
29
|
Affiliation(s)
- L Luzzatto
- National Institute for Cancer Research, Genova, Italy.
| | | |
Collapse
|
30
|
Midiri G, Consorti F, Giarnieri E, Soda G, Bosco D, Lorenzotti A, Luzzatto L, Conte S, Lo Russo M, Vecchione A, Beltrami V. [Genetics-based prognosis evaluation of patients surgically treated for sporadic colorectal cancer]. G Chir 2001; 22:165-8. [PMID: 11443839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
The basic assumption as rationale of this research was that DNA repair genes (MMR system) are at beginning of the genetic mutational cascade causing the induction of oncogenesis of sporadic colorectal cancers as well as their multiclonal heterogeneity. In a previous study the Authors randomly selected, from a series of 256 patients, 29 patients up to the age of 60 years who underwent surgery for colorectal carcinoma with radical intent. All selected cases were considered as sporadic cancers from a clinical point of view, since none of them fulfilled the Amsterdam criteria for HNPCC and familial adenomatous polyposis was included too. Mismatch repair gene proteins expression and, in particular, gene hMSH2 protein was investigated by immunohistochemistry analysis. In 12 cases (41.4%) hMSH2 exhibited strong expression in the tumoral cells as well as in the surrounding mucosa and at distant mucosa. In 14 cases (48.3%) loss of hMSH2 protein expression was observed in tumoral cells and low immunoreactivity was detected in peritumoral mucosa while strong hMSH2 expression was observed in distant mucosa. In a third small group of patients (10.3%) loss of hMSH2 protein expression was detected in tumoral, adjacent and at distance normal mucosa. After a five years follow up, 100% of twelve patients of first group are still alive vs 64.3% of fourteen patients of second group, while in the third group only one patient survives. These results support the hypothesis of an involvement of hMSH2 gene defect in development of a subset of sporadic colorectal cancer. For the patients with strong expression of hMSH2 in the tumoral cells as well as in the surrounding mucosa and at distant mucosa, this parameter could represent an independent criterion for a good prognostic value.
Collapse
Affiliation(s)
- G Midiri
- Università degli Studi La Sapienza, Roma
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
De Angioletti M, Rovira A, Notaro R, Camacho Vanegas O, Sadelain M, Luzzatto L. Glucose 6-phosphate dehydrogenase expression is less prone to variegation when driven by its own promoter. Gene 2001; 267:221-31. [PMID: 11313149 DOI: 10.1016/s0378-1119(01)00394-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The ability to transfer permanently genes into mammalian cells makes retroviruses suitable vectors for the ultimate purpose of treating inherited genetic disease. However, expression of the retrovirally transferred genes is variable (position effect and expression variegation) because retroviruses are highly susceptible to the influence of the host genome sequences which flank the integration site. We have investigated this phenomenon with respect to the human housekeeping enzyme, glucose 6-phosphate dehydrogenase (hG6PD). We have constructed retroviral vectors in which the hG6PD cDNA is driven by either of two conventional retroviral promoters and enhancers from the Moloney Murine Leukemia Virus (MMLV) and the Myeloproliferative Sarcoma Virus (MPSV) long terminal repeats (LTR) or by the hG6PD own promoter replacing most of enhancer and promoter LTR (GRU5). We have compared the activity of retrovirally transferred hG6PD driven by these promoters after retroviral integration in bulk cultures and in individual clones of murine fibroblasts. The level of hG6PD expressed by the hG6PD promoter of GRU5-G6PD was significantly lower than that expressed by conventional retroviral vectors. However, analysis of the single copy clones showed less variation of expression with GRU5-G6PD (coefficient of variation, CV, 35.5%) than with conventional vectors (CV, 58.9%). Thus we have several vectors competent for reliable transfer and expression of hG6PD. The hG6PD promoter provides reproducible expression of hG6PD and limits the variability of expression. This decreased variability is important in order to help ensuring a consistent level of delivery of the needed gene product in future therapeutic protocols.
Collapse
Affiliation(s)
- M De Angioletti
- Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
| | | | | | | | | | | |
Collapse
|
32
|
Karadimitris A, Gadola S, Altamirano M, Brown D, Woolfson A, Klenerman P, Chen JL, Koezuka Y, Roberts IA, Price DA, Dusheiko G, Milstein C, Fersht A, Luzzatto L, Cerundolo V. Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc Natl Acad Sci U S A 2001; 98:3294-8. [PMID: 11248072 PMCID: PMC30647 DOI: 10.1073/pnas.051604498] [Citation(s) in RCA: 149] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/20/2000] [Indexed: 12/21/2022] Open
Abstract
CD1 molecules are specialized in presenting lipids to T lymphocytes, but identification and isolation of CD1-restricted lipid specific T cells has been hampered by the lack of reliable and sensitive techniques. We here report the construction of CD1d-glycolipid tetramers from fully denatured human CD1d molecules by using the technique of oxidative refolding chromatography. We demonstrate that chaperone- and foldase-assisted refolding of denatured CD1d molecules and beta(2)-microglobulin in the presence of synthetic lipids is a rapid method for the generation of functional and specific CD1d tetramers, which unlike previously published protocols ensures isolation of CD1d tetramers loaded with a single lipid species. The use of human CD1d-alpha-galactosylceramide tetramers for ex vivo staining of peripheral blood lymphocytes and intrahepatic T cells from patients with viral liver cirrhosis allowed for the first time simultaneous analysis of frequency and specificity of natural killer T cells in human clinical samples. Application of this protocol to other members of the CD1 family will provide powerful tools to investigate lipid-specific T cell immune responses in health and in disease.
Collapse
Affiliation(s)
- A Karadimitris
- Nuffield Department of Medicine, Institute of Molecular Medicine, Oxford OX3 9DS, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Rovira A, De Angioletti M, Camacho-Vanegas O, Liu D, Rosti V, Gallardo HF, Notaro R, Sadelain M, Luzzatto L. Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer. Blood 2000; 96:4111-7. [PMID: 11110681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
Abstract
Many mutations of the housekeeping gene encoding glucose-6-phosphate dehydrogenase (G6PD) cause G6PD deficiency in humans. Some underlie severe forms of chronic nonspherocytic hemolytic anemia (CNSHA) for which there is no definitive treatment. By using retroviral vectors pseudotyped with the vesicular stomatitis virus G glycoprotein that harbor the human G6PD (hG6PD) complementary DNA, stable and lifelong expression of hG6PD was obtained in all the hematopoietic tissues of 16 primary bone marrow transplant (BMT) recipient mice and 14 secondary BMT recipients. These findings demonstrate the integration of a functional gene in totipotent stem cells. The average total G6PD in peripheral blood cells of these transplanted mice, measured as enzyme activity, was twice that of untransplanted control mice. This allowed the inference that the amount of G6PD produced by the transduced gene must be therapeutically effective. With the same vectors both the cloning efficiency and the ability to form embryoid bodies were restored in embryonic stem cells, in which the G6PD gene had been inactivated by targeted homologous recombination, thus effectively rescuing their defective phenotype. Finally, expression of normal human G6PD in hG6PD-deficient primary hematopoietic cells and in human hematopoietic cells engrafted in nonobese diabetic/severe combined immunodeficient mice was obtained. This approach could cure severe CNSHA caused by G6PD deficiency.
Collapse
Affiliation(s)
- A Rovira
- Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Karadimitris A, Notaro R, Koehne G, Roberts IA, Luzzatto L. PNH cells are as sensitive to T-cell-mediated lysis as their normal counterparts: implications for the pathogenesis of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2000; 111:1158-63. [PMID: 11167756 DOI: 10.1046/j.1365-2141.2000.02494.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The mechanism responsible for the bone marrow failure that is almost invariable in paroxysmal nocturnal haemoglobinuria (PNH) is unknown. Based on the close association between PNH and idiopathic aplastic anaemia, a plausible pathogenetic model predicts that, in PNH, autoreactive T cells specific for haemopoietic stem cells (HSCs) cause depletion of normal HSCs, whereas PNH HSCs escape this T-cell-mediated attack. In this study, we addressed the hypothesis that PNH HSCs are resistant to the cytotoxic effect of T cells because they lack surface expression of one or more glycosylphosphatidylinositol (GPI)-linked molecules. We tested the sensitivity of normal and PNH Epstein-Barr virus (EBV)-transformed B-cell lymphoblastoid cell lines (BLCLs) to the cytotoxic effect of autologous EBV-specific T-cell lines and clones from a patient with PNH in an in vitro experimental system. We found that the PNH BLCLs were no less sensitive to T-cell-mediated cytotoxicity than non-PNH isogenic BLCLs, indicating that GPI-linked molecules on the surface of target cells are not required for killing by T cells. This suggests that the mechanism whereby PNH HSCs survive T-cell attack is not because of the lack of surface expression of one or more GPI-linked molecules. By implication, other mechanisms become more probable.
Collapse
Affiliation(s)
- A Karadimitris
- Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | |
Collapse
|
35
|
Karadimitris A, Manavalan JS, Thaler HT, Notaro R, Araten DJ, Nafa K, Roberts IA, Weksler ME, Luzzatto L. Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood 2000; 96:2613-20. [PMID: 11001919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder of the hematopoietic stem cell (HSC). Somatic mutations in the PIG-A gene result in the deficiency of several glycosylphosphatidylinositol-linked proteins from the surface of blood cells. This explains intravascular hemolysis but does not explain the mechanism of bone marrow failure that is almost invariably seen in PNH. In view of the close relationship between PNH and idiopathic aplastic anemia (IAA), it has been suggested that the 2 disorders might have a similar cellular pathogenesis, namely, that autoreactive T-cell clones are targeting HSCs. In this paper, we searched for abnormally expanded T-cell clones by size analysis of the complementarity-determining region 3 (CDR3) in the beta variable chain (BV) messenger RNA (mRNA) of the T-cell receptor (TCR) in 19 patients with PNH, in 7 multitransfused patients with hemoglobinopathy. and in 11 age-matched healthy individuals. We found a significantly higher degree of skewness in the TCR BV repertoire of patients with PNH, compared with controls (R(2) values 0.82 vs 0.91, P <.001). The mean frequency of skewed families per individual was increased by more than 2-fold in patients with PNH, compared with controls (28% +/- 19.6% vs 11.4% +/- 6%, P =.002). In addition, several TCR BV families were significantly more frequently skewed in patients with PNH than in controls. These findings provide experimental support for the concept that PNH, like IAA, has an immune pathogenesis. In addition, the identification of expanded T-cell clones by CDR3 size analysis will help to investigate the effect of HSC-specific T cells on normal and PNH HSCs.
Collapse
Affiliation(s)
- A Karadimitris
- Department of Human Genetics and Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Giarnieri E, Consorti F, Lorenzotti A, Luzzatto L, Soda G, Bosco D, Vecchione A, Midiri G. Altered expression of hMSH2 in sporadic colorectal cancer, surrounding mucosa and at distant colonic mucosa. Anticancer Res 2000; 20:3829-31. [PMID: 11268462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
BACKGROUND Mismatch repair gene hMSH2 is involved in correction of mispairing during replication and its mutation is associated both with microsatellite instability and with hereditary colorectal cancer. We evaluated its involvement in sporadic colorectal cancer tumorigenesis too. MATERIALS AND METHODS The protein expression pattern of hMSH2 was evaluated on 29 cases of resected sporadic adenocarcinoma using an immunohistochemical approach. RESULTS In 14 cases, lack of hMSH2 protein expression was observed in adenocarcinoma and in peritumoral mucosa. In 12 patients, hMSH2 resulted in strong expression in the tumour as well as in the surrounding mucosa and at distant mucosa. In three cases, hMSH2 protein expression in tumoral, adjacent and at distance normal mucosa resulted negative. CONCLUSION Repair genes could play an important role in tumour progression and in sporadic colorectal cancer. Detection of protein expression by immunohistochemistry may be a method to select tumours for successive genetic investigations.
Collapse
Affiliation(s)
- E Giarnieri
- Dipartimento di Medicina Sperimentale, University La Sapienza di Roma, v.le del Policlinico, 00161 Roma, Italy
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Luzzatto L. Cloning, clones and clonal disease. J R Coll Physicians Lond 2000; 34:461-3. [PMID: 11077660 PMCID: PMC9665500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
In the past, cloning has been familiar to plant breeders because many plants can be easily reproduced in this way, bypassing the lengthy process of cross-fertilisation. Recently, the concept of cloning has become popular in human biology and medicine on two accounts. First, individual genes can be cloned from the enormous complexity of the DNA that makes up the human genetic material. It is expected that, within a few years, all the estimated 100,000 human genes will be isolated by this approach. This should make it possible to identify all the genes that determine the individual characteristics of human beings, including those responsible for causing human diseases or for making people more or less susceptible to pick up diseases from the environment. Cloned genes made into pharmaceutical products are already in use for treating a variety of diseases, from hormonal deficiencies to certain types of anaemia.
Collapse
Affiliation(s)
- L Luzzatto
- Department of Human Genetics, Memorial Sloan Kettering Cancer Center, New York, USA
| |
Collapse
|
38
|
May C, Rivella S, Callegari J, Heller G, Gaensler KM, Luzzatto L, Sadelain M. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000; 406:82-6. [PMID: 10894546 DOI: 10.1038/35017565] [Citation(s) in RCA: 428] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The stable introduction of a functional beta-globin gene in haematopoietic stem cells could be a powerful approach to treat beta-thalassaemia and sickle-cell disease. Genetic approaches aiming to increase normal beta-globin expression in the progeny of autologous haematopoietic stem cells might circumvent the limitations and risks of allogeneic cell transplants. However, low-level expression, position effects and transcriptional silencing hampered the effectiveness of viral transduction of the human beta-globin gene when it was linked to minimal regulatory sequences. Here we show that the use of recombinant lentiviruses enables efficient transfer and faithful integration of the human beta-globin gene together with large segments of its locus control region. In long-term recipients of unselected transduced bone marrow cells, tetramers of two murine alpha-globin and two human betaA-globin molecules account for up to 13% of total haemoglobin in mature red cells of normal mice. In beta-thalassaemic heterozygous mice higher percentages are obtained (17% to 24%), which are sufficient to ameliorate anaemia and red cell morphology. Such levels should be of therapeutic benefit in patients with severe defects in haemoglobin production.
Collapse
Affiliation(s)
- C May
- Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
| | | | | | | | | | | | | |
Collapse
|
39
|
Muro AF, Marro ML, Gajović S, Porro F, Luzzatto L, Baralle FE. Mild spherocytic hereditary elliptocytosis and altered levels of alpha- and gamma-adducins in beta-adducin-deficient mice. Blood 2000; 95:3978-85. [PMID: 10845937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
Abstract
The membrane skeleton, a dynamic network of proteins associated with the plasma membrane, determines the shape and mechanical properties of erythrocytes. Deficiencies or defects in membrane skeletal proteins are associated with inherited disorders of erythrocyte morphology and function. Adducin is one of the proteins localized at the spectrin-actin junction of the membrane skeleton. In this work we show that deficiency of beta-adducin produces an 80% decrease of alpha-adducin and a fourfold up-regulation of gamma-adducin in erythrocytes. beta-Adducin or any other isoform generated by translation of abnormally spliced messenger RNAs could not be detected by our antibodies either in ghosts or in cytoplasm of -/- erythrocytes. Actin levels were diminished in mutant mice, suggesting alterations in the actin-spectrin junctional complexes due to the absence of adducin. Elliptocytes, ovalocytes, and occasionally spherocytes were found in the blood film of -/- mice. Hematological values showed an increase in reticulocyte counts and mean corpuscular hemoglobin concentration, decreased mean corpuscular volume and hematocrit, and normal erythrocyte counts that, associated to splenomegaly, indicate that the mice suffer from mild anemia with compensated hemolysis. These modifications are due to a loss of membrane surface and dehydration that result in an increase in the osmotic fragility of red blood cells. The marked alteration in osmotic fragility together with the predominant presence of elliptocytes is reminiscent of the human disorder called spherocytic hereditary elliptocytosis. Our results suggest that the amount of adducin remaining in the mutant animals (presumably alphagamma adducin) could be functional and might account for the mild phenotype. (Blood. 2000;95:3978-3985)
Collapse
Affiliation(s)
- A F Muro
- International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
| | | | | | | | | | | |
Collapse
|
40
|
Luzzatto R, Poli M, Recktenvald M, Luzzatto L. Human papillomavirus infection in atrophic smears. A case report. Acta Cytol 2000; 44:420-2. [PMID: 10834003 DOI: 10.1159/000328490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Human papillomavirus (HPV) infection in atrophic smears can be misleading and may produce the diagnosis of cervical intraepithelial neoplasia. CASE A routine cervical smear in a 62-year-old female revealed an atrophic smear with nuclear changes suggestive of a high grade squamous intraepithelial lesion (HSIL). An estrogen cream for topical vaginal use was prescribed. A new smear was collected seven days later and revealed koilocytosis but no evidence of HSIL. CONCLUSION Koilocytosis is a cellular finding of mature epithelial cells. The use of estrogen produces maturation of HPV-infected basal cells, allowing a correct diagnosis of this disease in patients with atrophic smears.
Collapse
Affiliation(s)
- R Luzzatto
- Institute of Pathology, Porto Alegre, Rio Grande do Sul, Brazil
| | | | | | | |
Collapse
|
41
|
Abstract
Glucose 6-phosphate dehydrogenase (G6PD) is a cytosolic enzyme encoded by a housekeeping X-linked gene whose main function is to produce NADPH, a key electron donor in the defense against oxidizing agents and in reductive biosynthetic reactions. Inherited G6PD deficiency is associated with either episodic hemolytic anemia (triggered by fava beans or other agents) or life-long hemolytic anemia. We show here that an evolutionary analysis is a key to understanding the biology of a housekeeping gene. From the alignment of the amino acid (aa) sequence of 52 glucose 6-phosphate dehydrogenase (G6PD) species from 42 different organisms, we found a striking correlation between the aa replacements that cause G6PD deficiency in humans and the sequence conservation of G6PD: two-thirds of such replacements are in highly and moderately conserved (50-99%) aa; relatively few are in fully conserved aa (where they might be lethal) or in poorly conserved aa, where presumably they simply would not cause G6PD deficiency. This is consistent with the notion that all human mutants have residual enzyme activity and that null mutations are lethal at some stage of development. Comparing the distribution of mutations in a human housekeeping gene with evolutionary conservation is a useful tool for pinpointing amino acid residues important for the stability or the function of the corresponding protein. In view of the current explosive increase in full genome sequencing projects, this tool will become rapidly available for numerous other genes.
Collapse
Affiliation(s)
- R Notaro
- Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | |
Collapse
|
42
|
May J, Meyer CG, Grossterlinden L, Ademowo OG, Mockenhaupt FP, Olumese PE, Falusi AG, Luzzatto L, Bienzle U. Red cell glucose-6-phosphate dehydrogenase status and pyruvate kinase activity in a Nigerian population. Trop Med Int Health 2000; 5:119-23. [PMID: 10747271 DOI: 10.1046/j.1365-3156.2000.00529.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Glucose-6-phosphate dehydrogenase A- (G6PD A-) deficiency is a common enzymopathy in Africa that sporadically leads to manifest haemolytic anaemia. It is not exactly known how far the haematological status of individuals with either homozygous or heterozygous G6PD A- deficiency differs from that of individuals with normal G6PD activity. In a field study in Nigeria, we determined G6PD gene variants, the corresponding G6PD and pyruvate kinase (PK) activities, and basic haematological parameters in clinically healthy individuals, who were, in part, asymptomatically infected by malaria parasites. Red blood cell counts and haemoglobin levels were lower in G6PD A- deficient than in G6PD normal subjects. PK activities were higher in G6PD deficients, indicating a younger red cell population in these individuals. These findings suggest that G6PD A- deficiency is accompanied by chronic subclinical haemolysis. As a consequence, the reduced life span of red cells leads to an impaired diagnosis of G6PD heterozygosity when applying routine biochemical methods.
Collapse
Affiliation(s)
- J May
- Institute for Tropical Medicine, Medical Faculty Charité, Humboldt University Berlin, Berlin, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Midiri G, Lombardi A, Tesoriere A, Ferrazza P, Luzzatto L, Bosco D, Soda G, Di Paola M, Melis M. [Differential diagnostic problems between nodular fasciitis and soft-tissue sarcomas. A review of the literature and a case report]. G Chir 2000; 21:49-52. [PMID: 10732382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
After a review of literature and the report of a case with intrathoracic location, the authors consider present criteria for a correct diagnosis of low grade soft tissue sarcoma, when the possibility of nodular fasciitis is under evaluation. Nodular fasciitis is a benign pathology up to day not well characterised from the clinical and pathological point of view. The authors conclude that differential diagnosis between low grade soft tissue sarcoma and nodular fasciitis is frequently possible only on the basis of clinical course evaluation; otherwise the management may be inadequate.
Collapse
Affiliation(s)
- G Midiri
- Dipartimento di Scienze Chirurgiche e Tecnologie Mediche Applicate, Università degli Studi La Sapienza, Roma
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Araten DJ, Luzzatto L. Allogeneic bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica 2000; 85:1-2. [PMID: 10627666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
|
45
|
Oddoux C, Guillen-Navarro E, Ditivoli C, Dicave E, Cilio MR, Clayton CM, Nelson H, Sarafoglou K, McCain N, Peretz H, Seligsohn U, Luzzatto L, Nafa K, Nardi M, Karpatkin M, Aksentijevich I, Kastner D, Axelrod F, Ostrer H. Mendelian diseases among Roman Jews: implications for the origins of disease alleles. J Clin Endocrinol Metab 1999; 84:4405-9. [PMID: 10599695 DOI: 10.1210/jcem.84.12.6268] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The Roman Jewish community has been historically continuous in Rome since pre-Christian times and may have been progenitor to the Ashkenazi Jewish community. Despite a history of endogamy over the past 2000 yr, the historical record suggests that there was admixture with Ashkenazi and Sephardic Jews during the Middle Ages. To determine whether Roman and Ashkenazi Jews shared common signature mutations, we tested a group of 107 Roman Jews, representing 176 haploid sets of chromosomes. No mutations were found for Bloom syndrome, BRCA1, BRCA2, Canavan disease, Fanconi anemia complementation group C, or Tay-Sachs disease. Two unrelated individuals were positive for the 3849 + 10C->T cystic fibrosis mutation; one carried the N370S Gaucher disease mutation, and one carried the connexin 26 167delT mutation. Each of these was shown to be associated with the same haplotype of tightly linked microsatellite markers as that found among Ashkenazi Jews. In addition, 14 individuals had mutations in the familial Mediterranean fever gene and three unrelated individuals carried the factor XI type III mutation previously observed exclusively among Ashkenazi Jews. These findings suggest that the Gaucher, connexin 26, and familial Mediterranean fever mutations are over 2000 yr old, that the cystic fibrosis 3849 + 10kb C->T and factor XI type III mutations had a common origin in Ashkenazi and Roman Jews, and that other mutations prevalent among Ashkenazi Jews are of more recent origin.
Collapse
Affiliation(s)
- C Oddoux
- Department of Pediatrics, New York School of Medicine, New York 10016, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS, Brener D, Yang D, Kirstein L, Oddoux C, Ostrer H, Vineis P, Varesco L, Jhanwar S, Luzzatto L, Massagué J, Offit K. TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res 1999; 59:5678-82. [PMID: 10582683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
We have previously described a type I transforming growth factor (TGF)-beta receptor (TbetaR-I) polymorphic allele, TbetaR-I(6A), that has a deletion of three alanines from a nine-alanine stretch. We observed a higher than expected number of TbetaR-I(6A) homozygotes among tumor and nontumor DNA from patients with a diagnosis of cancer. To test the hypothesis that TbetaR-I(6A) homozygosity is associated with cancer, we performed a case-control study in patients with a diagnosis of cancer and matched healthy individuals with no history of cancer and who were identical in their gender and their geographical and ethnic background to determine the relative germ-line frequencies of this allele. We found nine TbetaR-I(6A) homozygotes among 851 patients with cancer. In comparison, there were no TbetaR-I(6A) homozygotes among 735 healthy volunteers (P < 0.01). We also observed an excess of TbetaR-I(6A) heterozygotes in cancer cases compared to controls (14.6% versus 10.6%; P = 0.02, Fisher's exact test). A subset analysis revealed that 4 of 112 patients with colorectal cancer were TbetaR-I(6A) homozygotes (P < 0.01). Using mink lung epithelial cell lines devoid of TbetaR-I, we established stably transfected TbetaR-I and TbetaR-I(6A) cell lines. We found that, compared to TbetaR-I, TbetaR-I(6A) was impaired as a mediator of TGF-beta antiproliferative signals. We conclude that TbetaR-I(6A) acts as a tumor susceptibility allele that may contribute to the development of cancer, especially colon cancer, by means of reduced TGF-beta-mediated growth inhibition.
Collapse
Affiliation(s)
- B Pasche
- Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Luzzatto L. Paroxysmal murine Hemoglobinuria(?): A model for human PNH. Blood 1999; 94:2941-4. [PMID: 10556175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
Affiliation(s)
- L Luzzatto
- Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| |
Collapse
|
48
|
Beutler E, Luzzatto L. Hemolytic anemia. Semin Hematol 1999; 36:38-47. [PMID: 10595753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
We entered the 20th century with only meager understanding of the erythrocyte. We leave this century with a relatively detailed understanding of the metabolism of the erythrocyte, the structure of its membrane, and the basis of genetic disorders that lead to its early demise in hemolytic anemia. Among the immune hemolytic disorders, the conquest of Rh hemolytic disease is one of the important clinical achievements of this century. Hereditary disorders of the membrane generally cause shape changes, such as spherocytosis or ovalocytosis. Paroxysmal nocturnal hemoglobinuria is the result of an acquired (somatic) mutation of PIG-A, an X-linked component of the glycosylphosphatidylinositol (GPI) anchor. Red cell enzyme deficiencies cause hereditary nonspherocytic hemolytic anemia. The mutations that cause the more common of these deficiencies are now well understood at the DNA level. Although much progress has been made, much is still to be learned. In particular, management of both acquired and hereditary hemolytic anemias is still very unsatisfactory. Often the only decision that can be made is whether to perform a splenectomy. In the future it is to be hoped that the knowledge that has been gained about these disorders in this century will make available better therapy to our patients in the next.
Collapse
Affiliation(s)
- E Beutler
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
| | | |
Collapse
|
49
|
Midiri G, Tesoriere A, Giarnieri E, Consorti F, Covotta A, Lorenzotti A, Urbano V, Luzzatto L, Bertolotti A, Vecchione A. [Genetic factors and colorectal cancer: a new approach to clinical experimentation]. G Chir 1999; 20:373-7. [PMID: 10444928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
The Authors point out the basis for a better characterisation of colo-rectal cancer and precursory lesions. In fact the etiology of familial adenomatous polyposis (FAP), aberrant crypt foci (ACF), hereditary non polyposis colon cancer syndrome (HNPCC) seems to be correlated to molecular pathology. Therefore the Authors review colo-rectal cancer natural history which frequently appears to be not related to clinical evolution.
Collapse
Affiliation(s)
- G Midiri
- Dipartimento di Scienze Chirurgiche e Tecnologie Mediche Applicate, Università degli Studi La Sapienza, Roma
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A 1999; 96:5209-14. [PMID: 10220445 PMCID: PMC21843 DOI: 10.1073/pnas.96.9.5209] [Citation(s) in RCA: 276] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
In paroxysmal nocturnal hemoglobinuria (PNH), acquired somatic mutations in the PIG-A gene give rise to clonal populations of red blood cells unable to express proteins linked to the membrane by a glycosylphosphatidylinositol anchor. These proteins include the complement inhibitors CD55 and CD59, and this explains the hypersensitivity to complement of red cells in PNH patients, manifested by intravascular hemolysis. The factors that determine to what extent mutant clones expand have not yet been pinpointed; it has been suggested that existing PNH clones may have a conditional growth advantage depending on some factor (e.g., autoimmune) present in the marrow environment of PNH patients. Using flow cytometric analysis of granulocytes, we now have identified cells that have the PNH phenotype, at an average frequency of 22 per million (range 10-51 per million) in nine normal individuals. These rare cells were collected by flow sorting, and exons 2 and 6 of the PIG-A gene were amplified by nested PCR. We found PIG-A mutations in six cases: four missense, one frameshift, and one nonsense mutation. PNH red blood cells also were identified at a frequency of eight per million. Thus, small clones with PIG-A mutations exist commonly in normal individuals, showing clearly that PIG-A gene mutations are not sufficient for the development of PNH. Because PIG-A encodes an enzyme essential for the expression of a host of surface proteins, the PIG-A gene provides a highly sensitive system for the study of somatic mutations in hematopoietic cells.
Collapse
Affiliation(s)
- D J Araten
- Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
| | | | | | | |
Collapse
|